Deutsches Krebsforschungszentrum

Chiesi Farmaceutici S.p.a.

Preclinics Ges. F. Praeklinische Forschung Mbh

Simone Ottonello

Angelo Bolchi

Martin Müller

Gino Villetti

Bruno Pietro Imbimbo

Xueer Zhao

Martin Mueller

Erik Schliebs

Ivonne Rubio

Somayeh Pouyanfard

Massimo Tommasino

Nadia Moretto

Jonas Fuener

Gloria Spagnoli

Filipe Mariz

Kathrin Balz

The present invention relates to an immunogenic polypeptide comprising a multitude of papillomavirus (PV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least four different cutaneous HPV genotypes; and to the aforesaid immunogenic polypeptide for use in medicine and for use in vaccination of a subject against cutaneous HPV infection and/or mucosal HPV infection. The present invention further relates to a polynucleotide encoding the aforesaid immunogenic polypeptide and to vectors, host cells, methods for producing an antibody, as well as antibodies related thereto.

Cutaneous papilloma virus vaccine

The invention relates to a novel VHH construct which can be bounded by a complete antibody without impairment of the antigen binding properties of the VHH construct being impaired. The invention also relates to an antibody construct comprising a VHH construct of this type and a kit, as well as the use thereof in immunodiagnostics or in the area of therapeutics. With the invention, among other things, it is possible to direct the existing immunity of a patient toward a different antigen.

VHH constructs for diverting an immune response

The present invention relates to an immunogenic polypeptide comprising a multitude of human papillomavirus (HPV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least two different HPV genotypes. The present invention also relates to said immunogenic polypeptide for use in medicine and for use in vaccination against HPV infection. Moreover, the present invention relates to a polynucleotide encoding the immunogenic polypeptide and to a host cell comprising the same. Moreover, the present invention relates to kits, methods, and uses related to the immunogenic polypeptide of the invention.

L2 peptide immunogenicity

The present invention relates to an immunogenic polypeptide comprising a) a scaffold polypeptide, and b) a L2 polypeptide or a fragment of said L2 polypeptide, wherein said scaffold polypeptide constrains the structure of said L2 polypeptide, or of a fragment of said L2 polypeptide. Moreover, the present invention relates to a vaccine comprising said immunogenic polypeptide. The present invention is also concerned with a method for producing an antibody against human papillomavirus. Also encompassed by the present invention is an antibody obtained by carrying out the said method.

Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or a fragment thereof

The present invention provides a recombinant immunogenic obtained by tandem multimerization of a B-cell epitope bearing fragment of A&#x3b2;42, within the active loop site of a carrier (display site), preferably bacterial thioredoxin (Yrx). Polypeptides bearing multiple copies of A&#x3b2;42 fragments, preferably with an interposed amino acid linker, were constructed and injected into mice in combination with an adjuvant. Elicited antibodies were found to selectively bind to fibrillar and/or oligomers A&#x3b2; within neuritic AD plaques.

Anti-amyloid immunogenic compositions, methods and uses

Growing community of inventors

Parma, Italy

Simone Ottonello